Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

Select a cancer below for additional information on ORP active trials at NCCN Member Institutions.

Breast Cancer

Gastrointestinal

Christos Fountzilas, MDRoswell Park Comprehensive Cancer CenterA Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
Amit Mahipal, MBBS, MPHMayo Clinic Cancer CenterPhase II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Biliary Tract Cancers
Sarbajit Mukherjee, MD, MSRoswell Park Comprehensive Cancer CenterUse of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma
Namrata Vijayvergia, MDNamrata Vijayvergia, MD Fox Chase Cancer CenterA Multi-Center Phase I trial of Neratinib and fam-trastuzumab deruxtecan in advanced refractory gastric cancer patients
Scott Plotkin, MDDana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer CenterPhase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305)

Head and Neck Cancers

Aarti Bhatia, MD, MPHYale Cancer Center/Smilow Cancer HospitalSingle-Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

Lung Cancer

Yasir Elamin, MDThe University of Texas MD Anderson Cancer CenterRandomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR)
Pasi Janne, MDDana-Farber/Brigham and Women's Cancer Center/ Massachusetts General HospitalA Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer
Joseph Treat, MDFox Chase Cancer CenterTH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked

Neurofibromatosisa

Martin McCarter, MDUniversity of Colorado Anschutz Medical CampusRandomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR)

Prostate Cancer

Scott Plotkin, MDDana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer CenterPhase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305)
Gurkamal Chatta, MDRoswell Park Comprehensive Cancer CenterA Phase IB Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by targeting DNA methyltransferase Activity